Antipsychotic prescribing practices for outpatients with schizophrenia and reasons for non-clozapine treatment - Data from a Danish quality assessment audit

References

• Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008;102(1-3):1–18.
   PubMed Web of Science ®Google Scholar
• Hastrup LH, Simonsen E, Ibsen R, et al. Societal costs of schizophrenia in Denmark: a nationwide matched controlled study of patients and spouses Before and After initial diagnosis. Schizophr Bull. 2020;46(1):68–77.
   PubMed Web of Science ®Google Scholar
• Penttilä M, Jääskeläinen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88–94.
   PubMed Web of Science ®Google Scholar
• Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Treatment-Resistant Schizophrenia - The role of clozapine. Curr Med Res Opin. 1997;14(1):1–20.
   PubMed Web of Science ®Google Scholar
• Wimberley TM, Støvring HP, Sørensen HJP, et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016;3(4):358–366.
   PubMed Web of Science ®Google Scholar
• Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231–3240.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981–1989.
   PubMed Web of Science ®Google Scholar
• Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of Treatment-Resistant schizophrenia. J Clin Psychiatry. 2019;80(2):18com12123.
   PubMed Web of Science ®Google Scholar
• Beck K, McCutcheon R, Stephenson L, et al. Prevalence of treatment-resistant psychoses in the community: a naturalistic study. J Psychopharmacol. 2019;33(10):1248–1253.
   PubMed Web of Science ®Google Scholar
• Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39–60.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Young C, Ifteni P, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149–161.
   PubMed Web of Science ®Google Scholar
• Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14(1):102.
   PubMedGoogle Scholar
• Masuda T, Misawa F, Takase M, et al. Association With hospitalization and All-Cause discontinuation Among patients With schizophrenia on clozapine vs other oral Second-Generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry. 2019;76(10):1052–1062.
   PubMed Web of Science ®Google Scholar
• Siskind D, McCartney L, Goldschlager R, et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–392.
   PubMed Web of Science ®Google Scholar
• Agid O, Arenovich T, Sajeev G, et al. An Algorithm-Based approach to First-Episode schizophrenia. J Clin Psychiatry. 2011;72(11):1439–1444.
   PubMed Web of Science ®Google Scholar
• Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):369–373.
   PubMed Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of Second-Generation antipsychotics in patients With Treatment-Resistant schizophrenia: a review and Meta-Analysis of randomized trials. Am J Psychiatry. 2001;158(4):518–526.
   PubMed Web of Science ®Google Scholar
• Siskind D, Siskind V, Kisely S. Clozapine response rates among people with Treatment-Resistant schizophrenia: data from a systematic review and Meta-Analysis. Can J Psychiatry. 2017;62(11):772–777.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients With Treatment-Refractory schizophrenia. J Clin Psychopharmacol. 2012;32(5):678–683.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Borlido C, Sanches M, et al. Adherence to clozapine vs. other antipsychotics in schizophrenia. Acta Psychiatr Scand. 2020;142(2):87–95.
   PubMed Web of Science ®Google Scholar
• Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al. Clozapine and Long-Term mortality risk in patients With schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull. 2019;45(2):315–329.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, International Suicide Prevention Trial Study Group, et al. Clozapine treatment for suicidality in SchizophreniaInternational suicide prevention trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.
   PubMed Web of Science ®Google Scholar
• Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder Among patients With co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32(4):637–643.
   PubMed Web of Science ®Google Scholar
• Frogley C, Taylor D, Dickens G, et al. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15(9):1351–1371.
   PubMed Web of Science ®Google Scholar
• Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and Self-Harm in association With clozapine in Treatment-Resistant schizophrenia. Am J Psychiatry. 2017;174(10):990–998.
   PubMed Web of Science ®Google Scholar
• Gee SH, Shergill SS, Taylor DM. Factors associated with changes in hospitalisation in patients prescribed clozapine. J Psychopharmacol. 2016;30(8):819–825.
   PubMed Web of Science ®Google Scholar
• Yada Y, Yoshimura B, Kishi Y. Correlation between delay in initiating clozapine and symptomatic improvement. Schizophr Res. 2015;168(1-2):585–586.
   PubMed Web of Science ®Google Scholar
• Üçok A, Çikrikçili U, Karabulut S, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2015;30(5):290–295.
   PubMed Web of Science ®Google Scholar
• Yoshimura B, Yada Y, So R, et al. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res. 2017;250:65–70.
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51.
   PubMed Web of Science ®Google Scholar
• Gören JL, Meterko M, Williams S, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv. 2013;64(6):527–533.
   PubMed Web of Science ®Google Scholar
• Doyle R, Behan C, OʼKeeffe D, et al. Clozapine use in a cohort of First-Episode psychosis. J Clin Psychopharmacol. 2017;37(5):512–517.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Røge R, Schjerning O, et al. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol. 2012;22(11):818–824.
   PubMed Web of Science ®Google Scholar
• Alessi-Severini S, Le Dorze J-A, Nguyen D, et al. Clozapine prescribing in a Canadian outpatient population. PLoS One. 2013;8(12):e83539-e.
   Web of Science ®Google Scholar
• Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother. 2008;42(6):852–860.
   PubMed Web of Science ®Google Scholar
• Patel MX, Bishara D, Jayakumar S, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol. 2014;24(4):499–509.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Dahm M, Lublin H, et al. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965–971.
   PubMed Web of Science ®Google Scholar
• Moore T, Covell NHP, Essock SMP, et al. Real-World antipsychotic treatment practices. Psychiatr Clin North Am. 2007;30(3):401–416.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25(5):383–399.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64(1):30–34.
   PubMed Web of Science ®Google Scholar
• Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481–485.
   PubMed Web of Science ®Google Scholar
• Lähteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273–1284.
   PubMed Web of Science ®Google Scholar
• Lally J, Gaughran F. Treatment resistant schizophrenia – review and a call to action. Ir J Psychol Med. 2019;36(4):279–291.
   PubMed Web of Science ®Google Scholar
• Baandrup L. Polypharmacy in schizophrenia. Basic Clin Pharmacol Toxicol. 2020;126(3):183–192.
   PubMed Web of Science ®Google Scholar
• Wheeler AJ, Feetam CL, Harrison J. Pathway to clozapine use: a comparison Between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig. 2014;34(3):203–211.
   PubMed Web of Science ®Google Scholar
• Baig AI, Bazargan-Hejazi S, Ebrahim G, et al. Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: a systematic review. Medicine (Baltimore). 2021;100(45):e27694-e.
   Web of Science ®Google Scholar
• Farooq S, Choudry A, Cohen D, et al. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJPsych Bull. 2019;43(1):8–16.
   PubMed Web of Science ®Google Scholar
• Thien K, O'Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review. Early Interv Psychiatry. 2019;13(1):18–23.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Quiles C, Bachmann CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res. 2018;201:10–19.
   PubMed Web of Science ®Google Scholar
• Legge SE, Hamshere M, Hayes RD, et al. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res. 2016;174(1-3):113–119.
   PubMed Web of Science ®Google Scholar
• Davis MC, Fuller MA, Strauss ME, et al. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr Scand. 2014;130(1):30–39.
   PubMed Web of Science ®Google Scholar
• Mustafa F, Burke J, Abukmeil S, et al. “Schizophrenia past clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry. 2015;48(1):11–14.
   PubMed Web of Science ®Google Scholar
• Krivoy A, Malka L, Fischel T, et al. Predictors of clozapine discontinuation in patients with schizophrenia. Int Clin Psychopharmacol. 2011;26(6):311–315.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Douglas-Hall P, Olofinjana B, et al. Reasons for discontinuing clozapine: matched, case–control comparison with risperidone long-acting injection. Br J Psychiatry. 2009;194(2):165–167.
   PubMed Web of Science ®Google Scholar
• Pai NB, Vella S. Reason for clozapine cessation. Acta Psychiatr Scand. 2012;125(1):39–44.
   PubMed Web of Science ®Google Scholar
• Nikolić N, Hill K, Campbell E, et al. Early access to clozapine in early intervention in psychosis: hope vs reality. A mixed method service analysis. Early Interv Psychiatry. 2021;15(1):193–200.
   PubMed Web of Science ®Google Scholar
• Leclerc L-D, Demers M-F, Bardell A, et al. A chart audit study of clozapine utilization in early psychosis. J Clin Psychopharmacol. 2021;41(3):275–280.
   PubMed Web of Science ®Google Scholar
• StatisticsDenmark. Population figures. 2022. https://www.dst.dk/en/Statistik/emner/borgere/befolkning/befolkningstal
   Google Scholar
• Sundhedsstyrelsen. National Klinisk Retningslinje for behandling af patienter med skizofreni og komplekse behandlingsforløb - vedvarende symptomer, misbrug eller mangelfuld behandlingstilknytning 2015. 2022. https://sundhedsstyrelsen.dk/da/udgivelser/2015/nkr-skizofreni
   Google Scholar
• StatisticsDenmark. Population at the first day of the quarter by region, sex, age and marital status. 2022. https://www.statistikbanken.dk/statbank5a/SelectVarVal/Define.asp?Maintable=FOLK1A&PLanguage=1
   Google Scholar
• Team RC. R: a language and environment for statistical computing. R.4.2.1. Vienna, Austria: R foundation for statistical computing; 2022.
   Google Scholar
• Hjorth S. The more, the merrier…? antipsychotic polypharmacy treatment strategies in schizophrenia From a pharmacology perspective. Front Psychiatry. 2021;12:760181.
   PubMed Web of Science ®Google Scholar
• Galling B, Roldán A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16(1):77–89.
   PubMed Web of Science ®Google Scholar
• Mortimer A, Singh P, Shepherd C, et al. Clozapine for treatment-resistant schizophrenia: national institute of clinical excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010;4(1):49–55.
   PubMedGoogle Scholar
• Ingimarsson O, MacCabe JH, Haraldsson M, et al. Clozapine treatment and discontinuation in Iceland: a national longitudinal study using electronic patient records. Nord J Psychiatry. 2016;70(6):450–455.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Coma A, Ibáñez C, et al. Antipsychotic polypharmacy in a regional health service: a population-based study. BMC Psychiatry. 2012;12(1):42.
   PubMedGoogle Scholar
• Barnes TRE, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the british association for psychopharmacology. J Psychopharmacol. 2020;34(1):3–78.
   PubMed Web of Science ®Google Scholar
• Siskind DJ, Lee M, Ravindran A, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52(8):751–767.
   PubMed Web of Science ®Google Scholar
• Chan HY, Pan YJ, Chen JJ, et al. Time to discontinuation of Second-Generation antipsychotics Versus haloperidol and sulpiride in people With schizophrenia: a naturalistic, comparative study. J Clin Psychopharmacol. 2017;37(1):13–20.
   PubMed Web of Science ®Google Scholar